Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is translocation renal cell carcinoma?
Most kidney cancers occur in older adults, but translocation renal cell carcinoma stands apart: it is part of the 'MiT family' of kidney cancers and is the most common kidney cancer in children and young adults, though it occurs at any age. It is defined by a specific genetic event — a translocation, where a piece of one chromosome breaks off and fuses to another, switching on the TFE3 gene (on the X chromosome) or, less often, the TFEB gene. This fusion acts as the master driver of the cancer. Some cases follow earlier chemotherapy in childhood. These tumors can look like ordinary clear cell or papillary kidney cancer, so molecular testing (a TFE3 or TFEB stain or fusion test) is needed to recognize them. They are notable for reaching the lymph nodes relatively early even when the kidney tumor is small, and for sometimes recurring many years — even decades — after surgery, which makes long-term follow-up important.
The main types
Doctors group translocation renal cell carcinoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| TFE3-rearranged (Xp11 translocation) RCC | The most common type, caused by fusion of the TFE3 gene with one of many partner genes; certain partners (such as ASPSCR1) behave more aggressively. |
| TFEB-rearranged (t(6;11)) RCC | A less common related type involving the TFEB gene; generally tends to behave somewhat less aggressively than TFE3 tumors. |
| TFEB-amplified RCC | A distinct, more aggressive group where the TFEB gene is multiplied rather than fused; recognized as higher-risk. |
Staging, in plain terms
Kidney cancers are staged by the size and local extent of the tumor (T), whether nearby lymph nodes are involved (N), and whether it has spread to distant organs (M). For translocation RCC, lymph-node involvement can appear even with smaller tumors, so the nodes are assessed carefully.
| Kidney (renal cell carcinoma) TNM | What it generally means |
|---|---|
| Stage I–II (localized) | Tumor confined to the kidney. Often curable with surgery, but because nodes can be involved early, careful staging and follow-up are important. |
| Stage III (locally advanced) | Tumor growing into nearby tissue or large veins, or reaching regional lymph nodes. Treated with surgery, often removing involved nodes. |
| Stage IV (distant spread) | Spread to distant lymph nodes, lungs, bone, or other organs. Treated with systemic targeted and immune therapy, sometimes with surgery or radiation to specific sites. |
The standard of care
Translocation Renal Cell Carcinoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery (the cornerstone for localized disease)
Removing the tumor — either the whole kidney (radical nephrectomy) or just the tumor (partial nephrectomy) — is the main treatment, often with removal of nearby lymph nodes because they can be involved early.
Immune checkpoint inhibitor therapy
Because these tumors often display high PD-L1, immunotherapy (sometimes combined with targeted drugs) is a key option for advanced disease, with some patients having exceptional, durable responses.
Targeted antiangiogenic drugs
VEGF-targeted tyrosine-kinase inhibitors (such as cabozantinib, sunitinib, or axitinib) — borrowed from clear cell kidney cancer — are used for metastatic disease, often together with immunotherapy.
Treating individual metastases
Because spread is sometimes limited, surgery or precise radiation can target single deposits in the lung, bone, or elsewhere to extend control.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide, while nearby normal tissue repairs itself. Kidney cancers were long thought to resist radiation, but modern high-dose, highly focused techniques like SBRT overcome that resistance by delivering ablative doses with pinpoint accuracy. In translocation RCC, radiation is used to control the primary tumor when surgery isn't possible, to treat individual metastases, and to relieve symptoms. It is delivered as a few short, painless sessions and leaves no radioactivity in your body, so you stay safe to be around others throughout.
The main ways radiation is delivered for translocation renal cell carcinoma:
Stereotactic body radiation therapy (SBRT)
Very precise, high-dose beams from many angles ablate the primary tumor in patients who can't have surgery, or treat individual metastases in bone, lung, or other sites in a few sessions.
Palliative radiation
Shorter courses of focused radiation relieve pain or other symptoms from bone or other metastases, improving quality of life.
Image-guided radiation (IGRT)
Daily imaging lets the team target moving kidney and abdominal tumors accurately while sparing the bowel, liver, and the opposite kidney.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
High PD-L1 supports immunotherapy: PD-L1 is expressed in the large majority of MiT-family translocation kidney cancers, and immune checkpoint inhibitors have produced exceptional, durable responses in selected patients, shaping current treatment.[1]
MiT-family RCC immunotherapy analyses (PMC6307255)
Fusion partner and chromosome loss affect outcome: ASPSCR1-TFE3 fusions and loss of regions such as 22q are linked to more aggressive disease, helping doctors predict behavior and intensify follow-up.[2]
Clinicopathologic series of TFE3-fusion RCC (PMC9295427; Frontiers Oncol 2021)
Late recurrence demands long follow-up: Translocation RCC can recur 20–30 years after the original diagnosis, so guidelines emphasize prolonged surveillance even after apparently successful surgery.[3]
MiT-family RCC reviews (PMC6721505)
Common questions
I'm young — why did I get kidney cancer? Translocation renal cell carcinoma is one of the few kidney cancers that commonly affects children and young adults. It's caused by a gene fusion (involving TFE3 or TFEB) that switches on the cancer — not by lifestyle — and in some cases follows chemotherapy given for an earlier childhood illness.
Why is molecular testing of my tumor important? Under the microscope these tumors can look like ordinary kidney cancers, but they behave differently and respond to specific therapies. A TFE3/TFEB stain or fusion test confirms the diagnosis so you get the right treatment and the right follow-up plan.
Why do I need follow-up for so many years? This cancer can come back a very long time after surgery — sometimes decades later. Long-term scans let your team detect any recurrence early, when it can often be treated effectively with surgery, targeted therapy, immunotherapy, or focused radiation.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- MiT-family RCC immunotherapy analyses (PMC6307255) (no indexed identifier — see your care team) ↩
- Clinicopathologic series of TFE3-fusion RCC (PMC9295427; Frontiers Oncol 2021) (no indexed identifier — see your care team) ↩
- MiT-family RCC reviews (PMC6721505) (no indexed identifier — see your care team) ↩